W. Tan

发表

Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer

A. Takano, E. Tan, Q. Ng, 2021, JAMA network open.

EGFR Mutation Subtypes Influence Survival Outcomes following First‐Line Gefitinib Therapy in Advanced Asian NSCLC Patients

E. Tan, Q. Ng, R. Kanesvaran, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

E. Tan, Q. Ng, D. Tan, 2018, BMC Cancer.

Advances in systemic treatment for nasopharyngeal carcinoma.

E. Tan, Q. Ng, D. Tan, 2016, Chinese clinical oncology.

Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer.

A. Takano, Q. Ng, R. Kanesvaran, 2022, JCO precision oncology.

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Jie Yang, M. Ahn, T. Mok, 2020 .

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

Jacob Josiah Santiago Alvarez, W. Tam, A. Takano, 2022, JTO clinical and research reports.

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities

Jacob Josiah Santiago Alvarez, W. Tam, D. Anantham, 2021, Clinical Cancer Research.

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

W. Tam, N. Iyer, W. Zhai, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel therapeutic targets on the horizon for lung cancer.

W. Tam, N. Iyer, W. Zhai, 2016, The Lancet. Oncology.

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.

T. Lim, A. Takano, E. Tan, 2019, Lung cancer.

Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer.

D. Tan, W. Tan, 2018, Translational lung cancer research.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

M. Ahn, T. Mok, H. Onishi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1338PEGFR mutation detection in plasma cell-free DNA correlates with clinical outcomes in non-small cell lung cancer

T. Chin, D. Chan, C. Toh, 2017 .

Molecular characterisation and clinical outcomes in RET rearranged non-small cell lung cancer (NSCLC).

A. Takano, E. Tan, Q. Ng, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of hepatocellular carcinoma in Eastern versus Western populations

A. Zhu, S. Choo, B. Goh, 2016, Cancer.

Is There a Unicorn Among the Uncommon EGFR Mutations?

D. Lim, W. Tan, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients

E. Tan, Q. Ng, R. Kanesvaran, 2017, Pharmacogenetics and genomics.

Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore.

E. Tan, Q. Ng, R. Kanesvaran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study

N. Iyer, W. Zhai, A. Takano, 2019, Journal of Thoracic Oncology.

From presentation to paper: Gender disparities in oncological research

M. V. van Oijen, R. Verhoeven, H. V. van Laarhoven, 2019, International journal of cancer.

Abstract 5114: Ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC)

Imane Bourzgui, A. Takano, E. Tan, 2022, Cancer Research.

The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung.

Q. Ng, W. Tan, 2016, Translational lung cancer research.

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma

B. Goh, M. Chua, N. Iyer, 2023, Nature communications.

Title: Dearth of smoking-induced mutations in NSRO-driven non-small-cell lung cancer despite smoking exposure Running title: Dearth of smoking mutations in NSRO-driven NSCLC Authors:

D. Anantham, A. Takano, E. Tan, 2023 .

Dearth of smoking-induced mutations in NSRO-driven non-small-cell lung cancer despite smoking exposure

W. Tam, D. Anantham, A. Takano, 2023, bioRxiv.

PD-L1 Score as a Prognostic Biomarker in Asian Early-Stage EGFR-Mutated Lung Cancer

A. Takano, E. Tan, Q. Ng, 2022, SSRN Electronic Journal.

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

E. Tan, Q. Ng, D. Tan, 2018, BMC Cancer.

PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.

A. Takano, E. Tan, Q. Ng, 2022, European journal of cancer.